Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MAHMOUD H BARAZI

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1942498803
CMS profile
314841
Location
EDINBURG, TX

General Payments · PY2018–2024

$11,099.88

  • Reported across 172 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$792.41

27 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $322.62 4
Amgen Inc. $188.62 5
Retrophin, Inc. $88.36 7
Relypsa, Inc. $63.66 4
Fresenius USA Marketing, Inc. $46.80 3
AKEBIA THERAPEUTICS INC $24.61 1
Averitas Pharma Inc. $23.40 1
Novo Nordisk AS $19.74 1
Lilly USA, LLC $14.60 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $286.25 13
PY2019 $3,174.31 21
PY2020 $4,385.96 16
PY2021 $1,057.19 16
PY2022 $612.25 37
PY2023 $791.51 42
PY2024 $792.41 27

Payment records · PY2024 (27)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AKEBIA THERAPEUTICS INC $24.61 11/12/2024 Education Undisputed 01/23/2026 1145834287 CMS
Amgen Inc. $20.80 04/02/2024 Food and Beverage Undisputed 01/23/2026 1111524492 CMS
Amgen Inc. $125.00 04/04/2024 Food and Beverage Undisputed 01/23/2026 1111524500 CMS
Amgen Inc. $12.12 06/12/2024 Food and Beverage Undisputed 01/23/2026 1111524494 CMS
Amgen Inc. $13.50 07/30/2024 Food and Beverage Undisputed 01/23/2026 1111524496 CMS
Amgen Inc. $17.20 10/30/2024 Food and Beverage Undisputed 01/23/2026 1111524498 CMS
AstraZeneca Pharmaceuticals LP $100.00 01/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1104315352 CMS
AstraZeneca Pharmaceuticals LP $100.00 01/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1105827417 CMS
AstraZeneca Pharmaceuticals LP $100.00 02/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1105759683 CMS
AstraZeneca Pharmaceuticals LP $22.62 02/21/2024 Food and Beverage Undisputed 01/23/2026 1104357759 CMS
Averitas Pharma Inc. $23.40 03/19/2024 Food and Beverage Undisputed 01/23/2026 1133428892 CMS
Fresenius USA Marketing, Inc. $13.28 05/16/2024 Food and Beverage Undisputed 01/23/2026 1154199196 CMS
Fresenius USA Marketing, Inc. $13.92 08/08/2024 Food and Beverage Undisputed 01/23/2026 1154199198 CMS
Fresenius USA Marketing, Inc. $19.60 10/02/2024 Food and Beverage Undisputed 01/23/2026 1154199200 CMS
Lilly USA, LLC $14.60 02/22/2024 Food and Beverage Undisputed 01/23/2026 1135153138 CMS
Novo Nordisk Inc $19.74 03/20/2024 Food and Beverage Undisputed 01/23/2026 1097045335 CMS
Travere Therapeutics, Inc. $9.87 01/23/2024 Food and Beverage Undisputed 01/23/2026 1149928831 CMS
Travere Therapeutics, Inc. $16.89 01/23/2024 Education Undisputed 01/23/2026 1149928854 CMS
Travere Therapeutics, Inc. $13.06 05/15/2024 Food and Beverage Undisputed 01/23/2026 1149928843 CMS
Travere Therapeutics, Inc. $13.76 06/26/2024 Food and Beverage Undisputed 01/23/2026 1149928847 CMS
Travere Therapeutics, Inc. $13.85 08/07/2024 Food and Beverage Undisputed 01/23/2026 1149928851 CMS
Travere Therapeutics, Inc. $10.52 09/17/2024 Food and Beverage Undisputed 01/23/2026 1149928839 CMS
Travere Therapeutics, Inc. $10.41 10/02/2024 Food and Beverage Undisputed 01/23/2026 1149928835 CMS
Vifor Pharma, Inc. $17.64 03/21/2024 Food and Beverage Undisputed 01/23/2026 1124034132 CMS
Vifor Pharma, Inc. $14.03 05/01/2024 Food and Beverage Undisputed 01/23/2026 1124034445 CMS
Vifor Pharma, Inc. $17.10 07/11/2024 Food and Beverage Undisputed 01/23/2026 1124056298 CMS
Vifor Pharma, Inc. $14.89 09/04/2024 Food and Beverage Undisputed 01/23/2026 1124053064 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.